This "trumpeting" may also partially explain the observed use of more Xience stents per lesion compared to Resolute (1.18Ϯ0.45 vs. 1.15Ϯ0.42, pϭ0.02) in the Resolute All Comers (RAC) trial. The primary cause for secondary stenting in RAC was "to stabilize target lesion" which includes procedural complications including dissection or perforations.
Background: Percutaneous intervention (PCI) for degenerated saphenous vein graft (SVG) lesions are well known for high rates of no-reflow, restenosis (ISR) and stent thrombosis. Covered stents have been tried in an aim to trap the debris to minimize no-reflow and ISR. Two types of covered stents have been used for SVG lesions: pericardium covered stent (PCS) & polytetrafluroethylene (PTFE) covered stent. We present our long-term follow-up data following the use of both types of covered stents in our practice. Methods: Between 1997 and 2004, 52 patients (mean age: 67.14 years) with 65 lesions in SVG were treated with PTFE covered stents as a part of multicenter trial (RECOV-ERS). Between 2003 and 2007, 33 patients (mean age: 67.78 years) with 48 SVG lesions were treated with pericardium-covered stents covered stents as a part of multicenter trial (SLEEVE II). Results: All case had TIMI3 flow post PCI and there were no immediate post-procedural complications. There were no significant differences in the baseline characteristics except that mean length of PCS were significantly longer than PTFE covered stents (32.3 mm vs 25.1 mm, pϽ0.001). At 5-year follow-up, the rates of TLR was [PTFE: 12 (18.5%), PCS: 13 (27%) pϭ0.17], TVR was [PTFE: 14 (21.5%), PCS: 16 (33%) pϭ0.07]. During the 5-year follow-up period, 8 patients (15%) in the PTFE group and 2 patients (6%) in the PCS group had died; pϭ0.33. The MACE defined as death, MI, clinically driven TVR occurred in 34 of 52 PTFE patients (63%) vs. 18 of 33 PCS patients (54.5%); pϭ0.2. There were two reported cases of definite very late stent thrombosis in the PCS group, but none in the PTFE group.
Conclusions:
The 5 year follow-up data shows no significant differences in the clinical endpoints between the two covered stents, although numerically it was slightly worse in the PCS group. The rates of TLR and TVR are not discouraging in either stents given the complexity of SVG lesions. Considering the complexity of the lesions treated and the absence of no-reflow, covered stents may provide additional protection. Since there are no very long-term follow-up with other stents in SVG, we cannot compare these results with the traditional stents.
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Background: In this study, we investigated the safety of ambulatory percutaneous coronary intervention (PCI) in high-risk patients according to age, creatinine, ejection fraction (ACEF) scores. Methods: The ambulatory PCI group consisted of all consecutive PCI with same-day discharges at Mount Sinai Hospital from January 1, 2003 to March 31, 2011 who had follow-up data. The overnight group consisted of all PCI outpatients in 2004 who were then hospitalized for at least one night. Patients were stratified into two groups based on ACEF score: low (Ͻ1.100) and high (Ն1.100). The primary endpoint was a 30-day major adverse cardiac events (MACE: readmission, all-cause death, and myocardial infarction (MI). Results: Out of 4932 patients, 3216 or 65.2% were in the ambulatory group and the rest (1716) were in the control group. The average age was 61.5 years and were no significant differences in baseline characteristics. Overall 30-day MACE occurred in similar frequency in both groups (Table) , in high and low ACEF scores. 
